NO762735L - - Google Patents
Info
- Publication number
- NO762735L NO762735L NO762735A NO762735A NO762735L NO 762735 L NO762735 L NO 762735L NO 762735 A NO762735 A NO 762735A NO 762735 A NO762735 A NO 762735A NO 762735 L NO762735 L NO 762735L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- formula
- methyl
- addition salts
- acid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000010933 acylation Effects 0.000 description 5
- 238000005917 acylation reaction Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- -1 1-(p-chlorophenoxy)-1-methylethyl Chemical group 0.000 description 1
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- BGQHPLYSXBZMQG-UHFFFAOYSA-N 4-(2-Hydroxy-3-tert-butylaminopropoxy)-2-methylindole Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(O)CNC(C)(C)C BGQHPLYSXBZMQG-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005359 phenoxyalkyl group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1071475 | 1975-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO762735L true NO762735L (fi) | 1977-02-16 |
Family
ID=4366041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO762735A NO762735L (fi) | 1975-08-15 | 1976-08-06 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US4434176A (fi) |
| JP (2) | JPS5223073A (fi) |
| AT (1) | AT363070B (fi) |
| AU (1) | AU505719B2 (fi) |
| BE (1) | BE845197R (fi) |
| CA (1) | CA1080720A (fi) |
| CY (1) | CY1225A (fi) |
| DE (1) | DE2635209C2 (fi) |
| DK (1) | DK152120C (fi) |
| ES (1) | ES450681A1 (fi) |
| FI (1) | FI63751C (fi) |
| FR (1) | FR2320743A2 (fi) |
| GB (2) | GB1575510A (fi) |
| HK (1) | HK35884A (fi) |
| IE (1) | IE43797B1 (fi) |
| IL (2) | IL50263A (fi) |
| KE (1) | KE3404A (fi) |
| MY (1) | MY8500135A (fi) |
| NL (2) | NL176362C (fi) |
| NO (1) | NO762735L (fi) |
| NZ (1) | NZ181764A (fi) |
| PH (1) | PH13356A (fi) |
| PT (1) | PT65477B (fi) |
| SE (1) | SE414633B (fi) |
| SG (1) | SG84883G (fi) |
| SU (1) | SU649313A3 (fi) |
| YU (1) | YU198876A (fi) |
| ZA (1) | ZA764883B (fi) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2830211A1 (de) * | 1977-07-21 | 1979-02-01 | Sandoz Ag | Substituierte indol-derivate, ihre herstellung und verwendung |
| JPS58106499A (ja) * | 1981-12-19 | 1983-06-24 | 株式会社東芝 | 燃料交換装置のクランプ解除機構 |
| NL8600137A (nl) * | 1985-02-05 | 1986-09-01 | Sandoz Ag | Farmaceutische preparaten die desgewenst met een diureticum gecombineerde 3-aminopropoxyindolen bevatten, alsmede werkwijzen voor het toepassen van deze preparaten. |
| US5174210A (en) * | 1990-04-27 | 1992-12-29 | Heidelberger Druckmaschinen Aktiengesellschaft | Preparation of the inking unit of a printing press for a change of printing job |
| WO1995020568A1 (en) * | 1994-01-28 | 1995-08-03 | Cal International Limited | Pharmaceutical product comprising a salicylate of an esterifiable beta-blocker |
| WO2004106299A2 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
| KR101329112B1 (ko) * | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
| WO2008020314A2 (en) * | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
| MX2009000439A (es) * | 2006-07-14 | 2009-02-04 | Ranbaxy Lab Ltd | Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH532040A (de) * | 1970-03-24 | 1972-12-31 | Sandoz Ag | Verfahren zur Herstellung neuer Indolderivate |
| US3751429A (en) * | 1970-03-24 | 1973-08-07 | Sandoz Ltd | 4-(3-amino-2-substituted propoxy)indole derivatives |
| SE375771B (fi) * | 1970-09-30 | 1975-04-28 | Sandoz Ag | |
| CH545783A (en) * | 1971-01-07 | 1974-02-15 | Novel indole derivs - prepn by reacting 4-(2-hydroxy-3-isopropylaminopropoxy) indoles and acid anhy-drides | |
| CH545784A (en) * | 1971-01-07 | 1974-02-15 | Beta blocking and anti-arrhythmic indole derivs - prepd by catalytic de-benzylation of 4-(3-benzyl aminopropoxy) indoles |
-
1976
- 1976-08-05 DE DE2635209A patent/DE2635209C2/de not_active Expired
- 1976-08-06 DK DK357576A patent/DK152120C/da not_active IP Right Cessation
- 1976-08-06 NO NO762735A patent/NO762735L/no unknown
- 1976-08-06 FI FI762258A patent/FI63751C/fi not_active IP Right Cessation
- 1976-08-06 SE SE7608865A patent/SE414633B/xx unknown
- 1976-08-11 NL NLAANVRAGE7608902,A patent/NL176362C/xx active Protection Beyond IP Right Term
- 1976-08-12 FR FR7624659A patent/FR2320743A2/fr active Granted
- 1976-08-12 YU YU01988/76A patent/YU198876A/xx unknown
- 1976-08-13 AU AU16841/76A patent/AU505719B2/en not_active Expired
- 1976-08-13 CA CA259,050A patent/CA1080720A/en not_active Expired
- 1976-08-13 ES ES450681A patent/ES450681A1/es not_active Expired
- 1976-08-13 IE IE1791/76A patent/IE43797B1/en not_active IP Right Cessation
- 1976-08-13 AT AT0602576A patent/AT363070B/de not_active IP Right Cessation
- 1976-08-13 NZ NZ181764A patent/NZ181764A/xx unknown
- 1976-08-13 GB GB13931/79A patent/GB1575510A/en not_active Expired
- 1976-08-13 CY CY1125A patent/CY1225A/xx unknown
- 1976-08-13 PT PT65477A patent/PT65477B/pt unknown
- 1976-08-13 ZA ZA00764883A patent/ZA764883B/xx unknown
- 1976-08-13 BE BE169821A patent/BE845197R/xx active
- 1976-08-13 IL IL50263A patent/IL50263A/xx unknown
- 1976-08-13 SU SU762388420A patent/SU649313A3/ru active
- 1976-08-13 PH PH18788A patent/PH13356A/en unknown
- 1976-08-13 GB GB33753/76A patent/GB1575509A/en not_active Expired
- 1976-08-14 JP JP51096629A patent/JPS5223073A/ja active Granted
-
1979
- 1979-09-03 IL IL58163A patent/IL58163A0/xx unknown
-
1980
- 1980-05-23 JP JP6800480A patent/JPS5649318A/ja active Pending
-
1982
- 1982-05-06 US US06/375,369 patent/US4434176A/en not_active Expired - Lifetime
-
1983
- 1983-12-29 SG SG848/83A patent/SG84883G/en unknown
-
1984
- 1984-04-19 KE KE3404A patent/KE3404A/xx unknown
- 1984-04-26 HK HK358/84A patent/HK35884A/xx unknown
-
1985
- 1985-12-30 MY MY135/85A patent/MY8500135A/xx unknown
-
1993
- 1993-07-02 NL NL930134C patent/NL930134I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1424730A3 (ru) | Способ получени метилсульфонамидофенилалкиламинов или их фармацевтически приемлемых солей | |
| JP5422545B2 (ja) | リン酸カルベジロール塩および／またはその溶媒和物、対応する組成物、および／または治療方法 | |
| US4125620A (en) | 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof | |
| EP0025111B1 (en) | 3-aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them | |
| US4288452A (en) | 1-Aryloxy-3-nitratoalkylamino-2-propanols and use as β-receptor blocker | |
| NO762735L (fi) | ||
| NO311565B1 (no) | Fremgangsmåte for spalting av racemisk ketamin | |
| US4340541A (en) | 4-(2-Benzoyloxy-3-tert.-butylaminopropoxy-2-methyl indole | |
| WO1991001957A1 (en) | Resolution of racemic mixtures | |
| US4235919A (en) | 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof | |
| US3267117A (en) | Novel substituted indol-5-ols | |
| NO150916B (no) | Analogifremgangsmaate ved fremstilling av et terapeutisk aktivt fenoksypropanolaminderivat | |
| NO803693L (no) | 2,3-indoldion-derivater. | |
| NO160864B (no) | Fremgangsmaate til fremstilling av et varmebehandlet nikkel-jern-basert legeringsprodukt. | |
| US4080463A (en) | 2-Substituted-aminopropoxy indoles | |
| JPS6222768A (ja) | 置換テトラヒドロイソキノリン誘導体 | |
| KR840001840B1 (ko) | 1-아릴옥시-3-알킬아미노-2-프로판올류의 제조방법 | |
| JPS6059230B2 (ja) | 不整脈抑制性フエネチルピペリジン化合物 | |
| NO833423L (no) | Fremgangsmaate for fremstilling av piperidinderivater for anvendelse ved hjerte/kretsloepforstyrrelser. | |
| US4161532A (en) | N-(1'-ethyl-2'-oxo-5'-pyrrolidinylmethyl) benzamide compounds and derivatives, method of preparation and pharmaceutical preparations | |
| JPS60105659A (ja) | Ｎ−ベンゾイルスルフアメ−ト、ｎ−ベンジルスルフアメ−トおよびベンジルスルホンアミド抗高脂血症剤 | |
| US4015002A (en) | 1-Aryl-2-oxo-2,4,5,6,7,7a-hexahydro-indoles, salts, pharmaceutical compositions and methods of use | |
| NO123429B (fi) | ||
| US4594344A (en) | 1-aryloxypropanolamines | |
| US5187284A (en) | N-phenyl-N'-benzothienylmethyl-bis-diamino-5-methylene-1,3-dioxane-4,6-dione derivatives |